These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 32197634)

  • 1. Novel combinations to improve hematopoiesis in myelodysplastic syndrome.
    Syed K; Naguib S; Liu ZJ; Cimmino L; Yang FC
    Stem Cell Res Ther; 2020 Mar; 11(1):132. PubMed ID: 32197634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Dysregulation and Recurring Mutations in Myelodysplastic Syndromes Pathogenesis.
    Matos A; Magalhães SMM; Rauh MJ
    Adv Exp Med Biol; 2021; 1326():1-10. PubMed ID: 33385175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor genetic alterations and features of the immune microenvironment drive myelodysplastic syndrome escape and progression.
    Montes P; Bernal M; Campo LN; González-Ramírez AR; Jiménez P; Garrido P; Jurado M; Garrido F; Ruiz-Cabello F; Hernández F
    Cancer Immunol Immunother; 2019 Dec; 68(12):2015-2027. PubMed ID: 31705171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting inflammation in lower-risk MDS.
    Gonzalez-Lugo JD; Verma A
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):382-387. PubMed ID: 36485128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia.
    Kurotaki H; Tsushima Y; Nagai K; Yagihashi S
    Acta Haematol; 2000; 102(3):115-23. PubMed ID: 10692673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
    Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
    Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis].
    Schmitt-Graeff A; Mattern D; Köhler H; Hezel J; Lübbert M
    Pathologe; 2000 Jan; 21(1):1-15. PubMed ID: 10663664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How predictive is the finding of clonal hematopoiesis for the development of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)?
    Steensma DP
    Best Pract Res Clin Haematol; 2021 Dec; 34(4):101327. PubMed ID: 34865699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Senescent Mesenchymal Stem Cells Contribute to Progression of Myelodysplastic Syndromes-Review].
    Pang YB; Li WW; Luo JM; Ji J; DU X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):942-946. PubMed ID: 29950248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone marrow macrophages are involved in the ineffective hematopoiesis of myelodysplastic syndromes.
    Xing T; Yao WL; Zhao HY; Wang J; Zhang YY; Lv M; Xu LP; Zhang XH; Huang XJ; Kong Y
    J Cell Physiol; 2024 Feb; 239(2):e31129. PubMed ID: 38192063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolving strategies in the treatment of MDS and AML.
    Stone R; Sekeres M; Garcia-Manero G
    Clin Adv Hematol Oncol; 2009 Aug; 7(8):1-14; quiz 2 p following 14. PubMed ID: 19927982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults.
    Babushok DV; Bessler M; Olson TS
    Leuk Lymphoma; 2016; 57(3):520-36. PubMed ID: 26693794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute Myeloid Leukemia Arising from Myelodysplastic Syndromes.
    Kwon A; Weinberg OK
    Clin Lab Med; 2023 Dec; 43(4):657-667. PubMed ID: 37865509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia.
    Bănescu C; Tripon F; Muntean C
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells.
    Rajapaksa R; Ginzton N; Rott LS; Greenberg PL
    Blood; 1996 Dec; 88(11):4275-87. PubMed ID: 8943864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease.
    Mohty R; Al Hamed R; Bazarbachi A; Brissot E; Nagler A; Zeidan A; Mohty M
    J Hematol Oncol; 2022 Aug; 15(1):124. PubMed ID: 36045390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Research progress on mechanism of MDS transformation into AML].
    Wang LL; Gao C; Chen BA
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):254-9. PubMed ID: 21362264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies for biology- and molecular-based treatment of myelodysplastic syndromes.
    Lindberg EH
    Curr Drug Targets; 2005 Sep; 6(6):713-25. PubMed ID: 16178803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biology of the bone marrow microenvironment and myelodysplastic syndromes.
    Rankin EB; Narla A; Park JK; Lin S; Sakamoto KM
    Mol Genet Metab; 2015; 116(1-2):24-8. PubMed ID: 26210353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
    Kaszuba CM; Rodems BJ; Sharma S; Franco EI; Ashton JM; Calvi LM; Bajaj J
    J Vis Exp; 2023 Nov; (201):. PubMed ID: 38009736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.